[go: up one dir, main page]

MX9303127A - Metodo para reducir selectivamente la poblacion celular de leucocitos. - Google Patents

Metodo para reducir selectivamente la poblacion celular de leucocitos.

Info

Publication number
MX9303127A
MX9303127A MX9303127A MX9303127A MX9303127A MX 9303127 A MX9303127 A MX 9303127A MX 9303127 A MX9303127 A MX 9303127A MX 9303127 A MX9303127 A MX 9303127A MX 9303127 A MX9303127 A MX 9303127A
Authority
MX
Mexico
Prior art keywords
leukocytes
cell population
selectively reducing
series
elevated levels
Prior art date
Application number
MX9303127A
Other languages
English (en)
Inventor
Janice North
Original Assignee
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Tech Inc filed Critical Quadra Logic Tech Inc
Publication of MX9303127A publication Critical patent/MX9303127A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe el tratamiento de una serie de compuestos de profirina utilizando un enfoque de terapia fotodinámica, que es capaz de disminuir selectivamente los niveles elevados de leucocitos activados en una población de leucocitos. Esto es particularmente útil en individuos que contienen tales niveles elevados de subseries de células T tales como individuos infectados con VIH.
MX9303127A 1992-05-27 1993-05-27 Metodo para reducir selectivamente la poblacion celular de leucocitos. MX9303127A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/889,707 US5776966A (en) 1992-05-27 1992-05-27 Selective cell inactivation in blood

Publications (1)

Publication Number Publication Date
MX9303127A true MX9303127A (es) 1994-06-30

Family

ID=25395640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9303127A MX9303127A (es) 1992-05-27 1993-05-27 Metodo para reducir selectivamente la poblacion celular de leucocitos.

Country Status (23)

Country Link
US (1) US5776966A (es)
EP (1) EP0642342B1 (es)
JP (1) JP3174821B2 (es)
KR (1) KR950701522A (es)
AT (1) ATE194491T1 (es)
AU (1) AU687734B2 (es)
CA (1) CA2136447C (es)
CZ (1) CZ283846B6 (es)
DE (1) DE69329026T2 (es)
DK (1) DK0642342T3 (es)
ES (1) ES2147754T3 (es)
FI (1) FI945586L (es)
GR (1) GR3034529T3 (es)
HU (1) HUT78021A (es)
IL (1) IL105815A (es)
MX (1) MX9303127A (es)
NO (1) NO308506B1 (es)
NZ (1) NZ252085A (es)
PT (1) PT642342E (es)
SK (1) SK143994A3 (es)
TW (1) TW257674B (es)
WO (1) WO1993024127A1 (es)
ZA (1) ZA933723B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807881A (en) * 1992-05-27 1998-09-15 Quadra Logic Technologies, Inc. Method for selectively reducing activated leukocyte cell population
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
CA2221912A1 (en) * 1997-11-21 1999-05-21 David Dolphin Photosensitizers with improved biodistribution and light-absorbing properties
US6117862A (en) 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
US6454789B1 (en) 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
CA2356532A1 (en) 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US6734192B1 (en) * 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2002064163A2 (en) 2001-02-15 2002-08-22 Qlt Inc. Reduction or prevention of pdt related inflammation
WO2002100326A2 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US20030103995A1 (en) * 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
JP2006506987A (ja) * 2002-06-28 2006-03-02 エクサイト セラピーズ インコーポレーティッド 自己免疫および臓器または造血幹細胞移植に関連する免疫学的欠損を有する患者における免疫レパートリー回復のための組成物および方法
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) * 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US7659301B2 (en) * 2003-04-15 2010-02-09 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
KR100604350B1 (ko) 2004-07-15 2006-07-25 학교법인 인제학원 광역학 치료용 광민감성 물질로 유용한 사이클릭테트라피롤 고분자와 이의 제조방법
ES2454974T3 (es) * 2007-06-27 2014-04-14 The General Hospital Corporation Aparato para la inhibición óptica de la terapia fotodinámica
PL233504B1 (pl) 2014-05-09 2019-10-31 Univ Jagiellonski Protoporfiryna IX kobaltu do stosowania w leczeniu neutropenii i białaczek
US10328085B2 (en) 2014-05-09 2019-06-25 Uniwersytet Jagiellonski Cobalt porphyrins for the treatment of blood-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610241A (en) * 1984-07-03 1986-09-09 Gordon Robert T Atherosclerosis treatment method
US5011684A (en) 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
DE3821254A1 (de) 1988-06-23 1990-01-04 Hoffmann Elektrokohle Schleifstueck fuer stromabnehmer sowie verfahren zu seiner herstellung
US5190966A (en) * 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US5028594A (en) * 1988-12-27 1991-07-02 Naxcor Use of photodynamic compositions for cytotoxic effects
US4960408A (en) * 1989-01-10 1990-10-02 Klainer Albert S Treatment methods and vaccines for stimulating an immunological response against retroviruses
US5149708A (en) * 1989-06-07 1992-09-22 University Of British Columbia Photosensitizing Diels-Alder porphyrin derivatives
US5087636A (en) * 1990-02-20 1992-02-11 University Of British Columbia Method to destroy malignant cells in mononuclear cell populations
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy

Also Published As

Publication number Publication date
PT642342E (pt) 2000-11-30
DE69329026D1 (de) 2000-08-17
AU4057193A (en) 1993-12-30
WO1993024127A1 (en) 1993-12-09
AU687734B2 (en) 1998-03-05
HUT78021A (hu) 1999-05-28
CZ291894A3 (en) 1995-09-13
HU9403385D0 (en) 1995-02-28
JPH08501278A (ja) 1996-02-13
ATE194491T1 (de) 2000-07-15
KR950701522A (ko) 1995-04-28
CA2136447C (en) 2001-06-19
DE69329026T2 (de) 2001-03-22
CA2136447A1 (en) 1993-12-09
FI945586A7 (fi) 1995-01-27
NO944537D0 (no) 1994-11-25
EP0642342A1 (en) 1995-03-15
GR3034529T3 (en) 2000-12-29
EP0642342B1 (en) 2000-07-12
SK143994A3 (en) 1996-07-03
NO944537L (no) 1995-01-20
US5776966A (en) 1998-07-07
IL105815A0 (en) 1993-09-22
DK0642342T3 (da) 2000-10-09
JP3174821B2 (ja) 2001-06-11
ES2147754T3 (es) 2000-10-01
CZ283846B6 (cs) 1998-06-17
TW257674B (es) 1995-09-21
FI945586L (fi) 1995-01-27
NO308506B1 (no) 2000-09-25
NZ252085A (en) 1998-02-26
IL105815A (en) 2000-01-31
FI945586A0 (fi) 1994-11-28
ZA933723B (en) 1993-12-15

Similar Documents

Publication Publication Date Title
MX9303127A (es) Metodo para reducir selectivamente la poblacion celular de leucocitos.
ES2084702T3 (es) Imidazoles sustituidos utiles como inhibidores de la angiotensina ii.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ES2055745T3 (es) Compuestos antigestagenicos y antiestrogenos para el tratamiento de tumores hormono-dependientes.
ES2091684T3 (es) Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
NO944997D0 (no) Trombin-blodfraksjon for anvendelse ved en medisinsk fremgangsmåte
MX9405383A (es) Imidazo(4,5-c) piridin-4-aminas.
ES2191192T3 (es) Tienopirimidinas.
ES2161697T3 (es) Peptidos agonistas de amilina y usos de los mismos.
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
AR009560A1 (es) Prolongacion de la sobrevida de injertos con porfirinas
ES2055587T3 (es) El uso de agonistas selectivos de gaba-b como agentes antitusivos.
ES2089687T3 (es) 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.
ES2051675T1 (es) Uso de ciertos herbicidas en el tratamiento del cancer y produccion de protoporfirina ix.
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
GT200300199A (es) Indoles 2,7-sustituidos
ES2114657T3 (es) Sistema catalitico utilizable para la polimerizacion de alfa-olefinas y procedimiento para esta polimerizacion.
ES2124327T3 (es) Derivados de sulfonamida aminometileno como inmunosupresores.
ES2166900T3 (es) Derivados de ara-c.
ATE68200T1 (de) Antioxidanz-produkte.
ES2061447T3 (es) Compuestos con efecto nootropo, agentes que los contienen y su empleo en el tratamiento y la profilaxis de disfunciones cognitivas.
ES2017764B3 (es) Procedimiento para el tratamiento de celulas primarias utilizadas
MX9302951A (es) Composicion farmaceutica para tratar la hiperproliferacion celular.
UY24100A1 (es) Nuevas sulfonamidas
ES2032914T3 (es) Procedimiento para preparar composiciones con diclorotrifluoetano.